| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | John F DiPersio | |
| Alaa M Ali | |||
| Mark A Schroeder | |||
| P2860 | cites work | High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation | Q84984871 |
| Serum microRNA155 is increased in patients with acute graft-versus-host disease | Q87228418 | ||
| IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines | Q24294720 | ||
| Molecular cloning and expression of human hepatocyte growth factor | Q24305558 | ||
| Interleukin-1 in the pathogenesis and treatment of inflammatory diseases | Q24606766 | ||
| Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. | Q53416418 | ||
| Increased expression of T cell immune response cDNA 7 in patients with acute graft-versus-host disease. | Q54294560 | ||
| Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease | Q57913856 | ||
| Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease | Q58814212 | ||
| Assessment of histopathologic changes in the colonic biopsy in acute graft-versus-host disease | Q72324318 | ||
| Serum hepatocyte growth factor levels in liver diseases: clinical implications | Q72371407 | ||
| IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade | Q73497705 | ||
| TNF-alpha and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway | Q73848126 | ||
| Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation | Q77400039 | ||
| Serum concentrations of hepatocyte growth factor in breast cancer patients | Q77556077 | ||
| Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease | Q80220196 | ||
| Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease | Q80283963 | ||
| Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD | Q82740456 | ||
| Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse | Q83071687 | ||
| Graft-versus-host disease | Q83468020 | ||
| Diagnosis and management of acute graft-versus-host disease | Q83992372 | ||
| Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system | Q84260223 | ||
| Biomarkers of immune activation to screen for severe, acute GVHD | Q84561184 | ||
| MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
| Elafin is a biomarker of graft-versus-host disease of the skin | Q24622918 | ||
| Circulating microRNAs as stable blood-based markers for cancer detection | Q24652098 | ||
| Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells | Q24658246 | ||
| Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response | Q27314881 | ||
| Cytokines in Graft-versus-Host Disease | Q28082195 | ||
| BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses | Q28507214 | ||
| MicroRNAs as biomarkers in solid organ transplantation | Q30414748 | ||
| A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera | Q30937297 | ||
| International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. | Q30994673 | ||
| Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease | Q34044170 | ||
| Diagnosis of gastrointestinal graft-versus-host disease | Q34092081 | ||
| Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease | Q34112417 | ||
| Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes | Q34127486 | ||
| Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma | Q34151439 | ||
| Graft-versus-host disease treatment: predictors of survival | Q34205096 | ||
| Proinflammatory S100 proteins in arthritis and autoimmune disease | Q34375738 | ||
| Reduced mortality after allogeneic hematopoietic-cell transplantation | Q34472861 | ||
| The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells. | Q34577694 | ||
| Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantation | Q34626032 | ||
| Keratin expression in human tissues and neoplasms | Q34636832 | ||
| Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease | Q34663913 | ||
| ST2: the biomarker at the heart of GVHD severity | Q34802351 | ||
| High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation | Q34802425 | ||
| TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines | Q34997144 | ||
| miR-155: on the crosstalk between inflammation and cancer | Q35006975 | ||
| A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study | Q35120338 | ||
| The TIM gene family: emerging roles in immunity and disease | Q35140798 | ||
| A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality | Q35177453 | ||
| The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. | Q35607302 | ||
| Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease | Q35623673 | ||
| Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial | Q35669901 | ||
| Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment | Q35820356 | ||
| Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. | Q35845324 | ||
| Plasma biomarkers of lower gastrointestinal and liver acute GVHD. | Q35891657 | ||
| Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study | Q35909700 | ||
| Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation | Q35970489 | ||
| Regulation of acute graft-versus-host disease by microRNA-155. | Q36010229 | ||
| Prevention of graft-versus-host disease by anti IL-7Ralpha antibody | Q36059590 | ||
| Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells | Q36106330 | ||
| First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation | Q36113205 | ||
| Hepatocyte growth factor levels in bone marrow plasma of patients with leukaemia and its gene expression in leukaemic blast cells | Q36134413 | ||
| Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. | Q36185219 | ||
| Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. | Q36363380 | ||
| How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver. | Q36727862 | ||
| Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. | Q36835126 | ||
| Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients | Q36961081 | ||
| A biomarker panel for acute graft-versus-host disease | Q37041904 | ||
| Association of serum interleukin-7 levels with the development of acute graft-versus-host disease | Q37103103 | ||
| Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease | Q37162874 | ||
| Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease | Q37291611 | ||
| ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death | Q37618997 | ||
| A novel soluble form of Tim-3 associated with severe graft-versus-host disease | Q37665262 | ||
| Regulatory T cells and IL-17-producing cells in graft-versus-host disease | Q37900645 | ||
| Potential biomarkers for early detection of acute graft-versus-host disease | Q38038568 | ||
| 1994 Consensus Conference on Acute GVHD Grading | Q39513397 | ||
| Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response | Q40327412 | ||
| Emerging multipotent aspects of hepatocyte growth factor | Q41066829 | ||
| Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells. | Q41121054 | ||
| Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease. | Q41178078 | ||
| Up-regulation of elafin/SKALP gene expression in psoriatic epidermis | Q42495342 | ||
| Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning | Q43198292 | ||
| Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation. | Q43533327 | ||
| Increased hepatocyte growth factor in serum in acute graft-versus-host disease | Q43710391 | ||
| Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems | Q44097093 | ||
| Monocyte-induced development of Th17 cells and the release of S100 proteins are involved in the pathogenesis of graft-versus-host disease. | Q44190611 | ||
| Simultaneous upper and lower endoscopic biopsy in the diagnosis of intestinal graft-versus-host disease | Q44662890 | ||
| Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil | Q46070193 | ||
| Importance of interleukin-7 in the development of experimental graft-versus-host disease | Q46173024 | ||
| Rotavirus as a significant cause of prolonged diarrhoeal illness and morbidity following allogeneic bone marrow transplantation | Q47605816 | ||
| Elafin: a possible new biomarker and immunohistochemical stain for pre-engraftment syndrome | Q47984037 | ||
| Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer | Q48881552 | ||
| TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. | Q49305656 | ||
| Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. | Q50798708 | ||
| Risk and prognostic factors for acute GVHD based on NIH consensus criteria. | Q53360412 | ||
| P433 | issue | 9 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 1552-1564 | |
| P577 | publication date | 2016-05-05 | |
| P1433 | published in | Biology of Blood and Marrow Transplantation | Q15754328 |
| P1476 | title | The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review | |
| P478 | volume | 22 |
| Q92210185 | A Preliminary Investigation towards the Risk Stratification of Allogeneic Stem Cell Recipients with Respect to the Potential for Development of GVHD via Their Pre-Transplant Plasma Lipid and Metabolic Signature |
| Q92756612 | A panel of 4 biomarkers for the early diagnosis and therapeutic efficacy of aGVHD |
| Q50545248 | A proposed biology- and biomarker-based algorithm for management of acute GvHD. |
| Q89297781 | A prospective study on serum Cytokeratin (CK)-18 and CK18 fragments as biomarkers of acute hepato-intestinal GVHD |
| Q93050836 | Acute Graft-Versus-Host Disease: A Brief Review |
| Q91254526 | Associations between febrile neutropenia-related parameters and the risk of acute GVHD or non-relapse mortality after allogeneic hematopoietic stem cell transplantation |
| Q90245997 | Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes |
| Q57281984 | Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes |
| Q41593355 | Dynamic changes in serum cytokine levels and their clinical significance in predicting acute GVHD. |
| Q33443876 | EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis |
| Q38635878 | Extracellular vesicles as potential biomarkers of acute graft-vs.-host-disease. |
| Q89820696 | Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD) |
| Q59333340 | GVHD: biology matters |
| Q90029154 | GVHD: biology matters |
| Q50630576 | Graft-versus-Host Disease of the Gut: A Histologic Activity Grading System and Validation |
| Q52667946 | Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Prediction but Indicates Treatment Safety. |
| Q47246973 | Methods and practices to diversify cell-based products |
| Q58050171 | Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease |
| Q91137776 | Serum biomarkers for diagnosis and prediction of type 1 diabetes |
| Q51555000 | The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays. |
Search more.